Purchase this article with an account.
L.B. Cantor, J. Hoop, L. Morgan, Bimatoprost–Travoprost Study Group; IOP–Lowering Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients With Glaucoma or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2451.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the IOP–lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension. Methods: Randomized, investigator–masked, parallel–group clinical trial. After completing a washout from all glaucoma medications, patients (n=158) were randomized to bimatoprost or travoprost for 6 months. Visits were at baseline, week 1, and months 1, 3, and 6. IOP was measured at 9 AM at each visit and also at 1 and 4 PM at baseline and months 3 and 6. This is an interim analysis of an ongoing clinical trial. Results: At the baseline visit, there were no significant between–group differences in IOP at 9AM, 1PM, or 4PM (P>.731). After 6 months of therapy, both medications provided significant mean reductions from baseline IOP at every time point (P<.001). Bimatoprost provided greater mean IOP reductions from baseline than travoprost at every time point at each follow up study visit and these differences were statistically significant at every visit at 9AM. After 6 months of therapy, the mean IOP reduction at 9AM was 7.2 mm Hg (28.3%) with bimatoprost (n=63) and 5.4 mm Hg (22.3%) with travoprost (n=60) (P=.005). At 1PM, the mean IOP reduction was 6.0 mm Hg with bimatoprost (25.7%) and 4.9 mm Hg (21.1%) with travoprost (P=.058). Finally, bimatoprost continued to provide greater IOP lowering than travoprost at 4 PM, with a mean bimatoprost–provided IOP reduction of 5.5 mm Hg (23.3%) versus a mean travoprost–provided IOP reduction of 4.3 mm Hg (18.1%, P=.086). Both study medications were well tolerated and ocular redness was the most commonly reported adverse event in both treatment groups. Conclusions: Bimatoprost provided greater mean IOP reductions than travoprost.
This PDF is available to Subscribers Only